



Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification

Francesca Carbonara¹ · Tiziana Feola^{2,3} · Francesca Gianno^{2,4} · Michela Anna Polidoro^{1,5} · Rosa Maria Di Crescenzo^{2,6} · Antonietta Arcella² · Michelangelo De Angelis² · Roberta Morace² · Dario de Alcubierre³ · Vincenzo Esposito^{2,7} · Felice Giangaspero^{2,4} · Marie-Lise Jaffrain-Rea^{1,2}

Accepted: 20 November 2023
© The Author(s) 2023

Abstract

Since 2017, hormone-negative pituitary neuroendocrine tumors expressing the steroidogenic factor SF1 have been recognized as gonadotroph tumors (GnPT) but have been poorly studied. To further characterize their bio-clinical spectrum, 54 GnPT defined by immunostaining for FSH and/or LH (group 1, $n = 41$) or SF1 only (group 2, $n = 13$) were compared and studied for *SF1*, *βFSH*, *βLH*, *CCNA2*, *CCNB1*, *CCND1*, *caspase 3*, *D2R*, and *AIP* gene expression by qRT-PCR. Immunohistochemistry for AIP and/or D2R was performed in representative cases. Overall, patients were significantly younger in group 1 ($P = 0.040$ vs group 2), with a similar trend excluding recurrent cases ($P = 0.078$), and no significant difference in gender, tumor size, invasion or Ki67. *SF1* expression was similar in both groups but negatively correlated with the patient's age ($P = 0.013$) and positively correlated with *βLH* ($P < 0.001$) expression. *Beta-FSH* and *AIP* were significantly higher in group 1 ($P = 0.042$ and $P = 0.024$, respectively). Ki67 was unrelated to gonadotroph markers but positively correlated with *CCNB1* ($P = 0.001$) and negatively correlated with *CCND1* ($P = 0.008$). *D2R* and *AIP* were strongly correlated with each other ($P < 0.001$), and both positively correlated with *SF1*, *βFSH*, *βLH*, and *CCND1*. AIP immunopositivity was frequently observed in both groups, with a similar median score, and unrelated to Ki67. D2R immunostaining was best detected with a polyclonal antibody and mostly cytoplasmic. This study indicates that hormone-negative GnPT tend to occur in older patients but do not significantly differ from other GnPT in terms of invasion or proliferation. It also points out the current limits of D2R immunostaining in such tumors.

Keywords Pituitary neuroendocrine tumors (PitNETs) · Gonadotroph tumors · SF1 · Dopamine receptor 2 (D2R) · Cell cycle · Aryl hydrocarbon receptor interacting protein (AIP)

Introduction

A large subset of pituitary neuroendocrine tumors (PitNETs) derives from gonadotroph cells. Most gonadotroph PitNETs (GnPT) do not secrete sufficient amounts of biologically active hormones to determine clinical features of

Pr. Felice Giangaspero accidentally died before the submission of this manuscript but was actively involved in the study. Written authorization to include his name among the authors was signed by his legal representant.

✉ Marie-Lise Jaffrain-Rea
marielise.jaffrain@univaq.it

¹ Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

² Neuromed IRCCS, Pozzilli, Italy

³ Department of Experimental Medicine, La Sapienza University of Rome (RM), Rome, Italy

⁴ Department of Radiological, Oncological and Pathological Sciences, La Sapienza University of Rome (RM), Rome, Italy

⁵ Hepatobiliary Immunopathology, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy

⁶ Department of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, Naples, Italy

⁷ Department of Neurology and Psychiatry, La Sapienza University of Rome (RM), Rome, Italy

hypersecretion and present as non-functioning pituitary tumors (NFPT) revealed by mass effects and/or endocrine dysfunction, including hypogonadism [1, 2]. Indeed, hypergonadism is rare, and the ovarian hyperstimulation syndrome was estimated to occur in about 3% of pre-menopausal women with a NFPT and 8% in those displaying immunoreactivity for gonadotropins [2]. Thus, most cases are diagnosed after surgery, based on immunohistochemical staining for gonadotropins and/or, since 2017, the steroidogenic factor 1 (SF1) [3, 4]. SF1 (also known as NR5A1), a transcription factor involved in the differentiation of gonadotroph cells, is currently considered the most sensitive and specific diagnostic marker of GnPT [5] and is especially useful in hormone-negative PitNETs or in the presence of equivocal staining for gonadotropins [6]. In a very large surgical series of PitNETs ($n > 1000$), up to 2/3 of hormone-negative PitNETs turned out to express SF1 only, thereby increasing the proportion of GnPT from 58 to 73% [7]. Overall, the molecular basis of GnPT has been less extensively studied than in other pituitary tumor subtypes [8], and the current knowledge would benefit from some revisions based on the current pathological definition of GnPT. To the best of our knowledge, potential bio-clinical differences between FSH/LH immuno-positive and pure SF1-expressing (pSF1) GnPT have not been specifically addressed.

The first therapeutic option in GnPT is surgery, and in the presence of post-operative tumor regrowth, re-operation and/or radiotherapy are generally recommended [1]. Indeed, no drug is currently approved for their medical treatment, although a subset of clinically NFPT may benefit from dopamine-agonists (DA), in particular cabergoline (CAB), with a moderate tumor shrinkage and/or stabilization reported in a majority of patients [9]. DA have also been used with some success in functional GnPT [10]. For such reasons, DA may be proposed as an alternative to radiotherapy in selected NF/GnPT after surgery [9]. Tumor shrinkage in NFPT has been variably associated with the expression of the dopamine receptor type 2 (D2R) [11–13]. However, factors influencing D2R expression in GnPT are poorly known.

In previous studies, we and other authors reported that the aryl hydrocarbon receptor interacting protein (AIP), which was identified in 2006 as a tumor suppressor gene in GH- and/or PRL-secreting PitNETs [14] and currently represents the main predisposing gene for the development of such tumors [15, 16], could be paradoxically overexpressed in NF/GnPT [17, 18]. Indeed, the pituitary expression of AIP was found to be normally restricted to somatotrophs and lactotrophs [17, 18], suggesting the presence of abnormal mechanisms of AIP regulation in GnPT. GnPT are also less frequently reported in familial isolated pituitary adenomas (FIPA) or in the presence of germline *AIP* mutations [15]. AIP overexpression may be essentially limited to a subset of GnPT with a high Ki67 [19]. However, this has not been

confirmed yet, and the biological significance of AIP expression in GnPT has not been further explored.

In this study, we aimed to provide new insight in some molecular characteristics of GnPT according to the expression of FSH/LH and/or SF1 only. We focused our attention on the relationship between *SF1*, *β LH*, and *β FSH* gene expression and representative markers of cell cycle, as well as *D2R* and *AIP*. We also attempted to further characterize pSF1 tumors as compared to other GnPT from a translational point of view.

Material and Methods

Patients and Tumors

Surgical biopsies of 54 GnPT operated on at the Neuromed Institute (Pozzilli, IS, Italy) were studied. All patients (37 M, 17 F, median age 59 years, range 36–83) were operated on for medical reasons, most of them by a transsphenoidal route ($n = 52$). For each patient, pre-operative data were collected, including hormone assays (PRL, FSH, LH, testosterone in males, estradiol in females) and magnetic resonance imaging (MRI). All were macrotumors (maximal diameter > 1 cm), including 12 giant tumors (≥ 4 cm). Invasiveness was defined according to pre-operative MRI and intra-operative findings. Immunohistochemistry was carried out on 4- μ m thickness sections, using an automatic immunostaining Benchmark ultra XT (Ventana), and an Ultra View DAB Detection Kit (Roche Diagnostic) for antibody signal detection. Immunohistochemical staining was obtained for all pituitary hormones, Ki67, and SF1 as appropriate [6]. The pathological diagnosis of GnPT was based on the WHO classification [3, 4] and tumors were divided into 2 groups according to their immunohistochemical profile: group 1 (FSH/LH), group 2 (pSF1). The following antibodies and conditions were used for diagnostic purposes: β FSH (prediluted, Roche), β LH (prediluted, Roche), SF1 (Ab217317 dil 1:500), and Ki67 (MIB1 antibody, Diagnostic Brokers Associated, Milan, Italy). The Ki67 labeling index of cell proliferation (Ki67 LI) was calculated on 500 to 1000 cells after image acquisition on a camera and manual count, considering hotspot areas where present [6]. A cut-off of 3% was used to define “high Ki67” tumors ($\geq 3\%$) or “low Ki67” tumors ($< 3\%$). Surgical samples from 3 normal post-mortem pituitaries (NP) were used for all gene expression studies, whereas a small number of functional lactotroph tumors (clinically defined before surgery and confirmed by unequivocal and exclusive PRL immunostaining) were used as controls for *D2R* gene expression ($n = 13$) and/or protein expression by immunohistochemistry (IHC) ($n = 9$). The study was performed according to the guidelines of the Declaration of Helsinki and approved by the Internal Review

Board of the Neuromed Institute (Pozzilli, Italy). Written informed consent was obtained from the patients, except for a minority of archive RNA or paraffin-embedded material from patients lost to follow-up.

Gene Expression Analysis

Surgical biopsies were collected in RNAlater stabilization solution (Ambion®, Life Technologies, Monza, Italy) at room temperature and subsequently frozen at $-80\text{ }^{\circ}\text{C}$ until use. Total RNA was extracted by TRIzol™ Reagent (Ambion®, Life Technologies, Monza, Italy). After DNase treatment (New England Biolabs), 500 ng of RNA-treated solution was reverse transcribed with Wonder RT (Euroclone, Pero, Italy) according to the manufacturer's instructions. Preliminary RT-PCR amplification of GAPD(H) was performed to ensure cDNA quality, including PCR on total DNase-treated RNA to exclude the presence of genomic DNA. RT-PCR for Pit-1 and Tpit was performed in order to exclude sample contamination by normal pituitary as previously described [20]. Gene expression was studied by semi-quantitative Real-Time RT-PCR using the Taqman methodology on an Applied Biosystems 7500 Fast Real-Time PCR and ready-to-use gene expression assays (Applied Biosystems, Life Technologies, Monza, Italy) for genes encoding SF1/NR5A1 (Hs00610436_m1), β FSH (Hs00174919_m1), β LH (Hs00751207_m1), cyclin D1 (*CCND1*, Hs00765553_m1), cyclin A2 (*CCNA2*, Hs00996788_m1), cyclin B1 (*CCNB1*, Hs01030099_m1), caspase 3 (Hs00234387_m1), AIP (Hs00610222_m19), D2R (Hs00241436_m1), and β -actin (Hs_99999903) as a house-keeping gene. The Taqman probe for D2R recognized both the short and long isoforms of D2R transcripts. All experiments were run at least in duplicate.

Immunohistochemistry (IHC)

IHC was performed on paraffin-embedded sections as described hitherto. Two commercial antibodies were tested for D2R expression: a monoclonal antibody (mab9266–100, R&D system, distributed by Aurogene, Italy, referred to as D2R-mAb, dilution 1:100) and a polyclonal antibody (AB5084P, Sigma-Aldrich, distributed by Sial, Italy, referred to as D2R-pAb, dilution 1:500), the latter being previously used in this indication [12, 13]. Brain sections from epilepsy surgery (temporal lobe) were primarily used as positive controls to set experimental conditions for both antibodies, and these were subsequently tested on normal pituitary fragments contaminating pituitary tumor samples. Endothelial cell immunostaining was also used as an internal control for D2R protein expression (D2R-pAb). A monoclonal anti-AIP (clone 35–2, NOVUS Biologicals LLC, Littleton, CO, USA) was used as previously described, using a similar

semiquantitative-based score and the intensity and pattern of AIP immunostaining (score 0–6) [21]. AIP immunopositivity was defined by a score ≥ 2 [19, 21] and high AIP-IHC by an AIP score ≥ 4 . A qualitative evaluation was provided for D2R immunostaining.

Statistical Analysis

Statistical analysis was performed using GraphPad Prism v10.0.2. Continuous data were expressed in median (range) and analyzed by non-parametric tests: Mann–Whitney test for two groups-analysis, Kruskal–Wallis for multiple comparisons, and Spearman test for correlation studies. One-tailed or two-tailed analyses were performed for two group comparisons, as appropriated. Categorical values were compared by the Chi-square test. $P < 0.05$ was considered significant.

Results

General Results

The main clinical, pathological, and molecular characteristics of patients and tumors are summarized in Table 1 and illustrated in Fig. 1A–C. A male predominance was observed in both groups, and at the time of surgery, patients were significantly younger in group 1 (median age 58 vs 67 years in group 2, $P = 0.040$). A similar trend was found excluding recurrent tumors, which could impact on patients' age (median age 54 years in group 1 vs 61 years in group 2, $P = 0.078$). No significant differences were found between the two groups in terms of tumor size, invasiveness, and proliferation index. Details about data obtained in recurrent tumors are provided in Supplemental Table 1.

Relationship Between Tumor SF1 mRNA and the Clinical/Molecular Characteristics of GnPT

From a clinical point of view, an inverse and significant relationship was observed between *SF1* transcripts and patients' age ($r = -0.339$, $P = 0.013$), and a similar relationship was found excluding recurrent cases ($r = -0.382$, $P = 0.013$) (Table 2). Accordingly, *SF1* transcripts were significantly lower in tumors operated from patients aged ≥ 65 years at the time of surgery as compared to younger patients ($P = 0.008$) (Supplemental Fig. 1). In contrast, no significant difference was found in *SF1* expression according to gender, tumor size, or invasiveness (data not shown).

Gene expression data obtained in the 2 groups are also summarized in Table 1. As shown in Fig. 1D–G, *SF1* mRNA expression did not significantly differ between the two groups and neither did *β LH*. In contrast, *β FSH* and *AIP* transcripts were significantly higher in group 1 as compared to group 2 ($P = 0.042$ and $P = 0.024$, respectively).

Table 1 Bio-clinical and molecular characteristics of GnPT according to the presence or the absence of gonadotropin immunostaining

	FSH/LH	SF1	P
I. Clinicopathological data			
Number of patients	41	13	
Gender	30 M; 11 F	7 M; 6 F	ns
Age (years)	58 (36–83)	67 (41–76)	0.040
Tumor size [cm]	3.20 [1.40–5.30]	3.00 [2.00–4.50]	ns
Giant (%)	9/40 (22.5%)	3/13 (23.1%)	ns
Invasive tumors	25/40 (62.5%)	7/13 (53.8%)	ns
Recurrent	4/41 (9.8%)	3/13 (23.1%)	ns
Ki67 (%)	2.50 (0.10–6.20)	2.30 (0.20–8.0)	ns
II. Gene expression			
<i>SF1/βactin</i> mRNA	19.1 [0.13–492.0]	21.4 [2.02–179]	ns
<i>βFSH/βactin</i> mRNA	66.9 [0.43–1067]	19.2 [0.61–680]	0.042
<i>βLH/βactin</i> mRNA	35.0 [0.23–4820]	9.74 [0.02–351]	ns
<i>CCND1/βactin</i> mRNA	16.0 [1.18–98.1]	18.2 [1.94–115]	ns
<i>CCNA2/βactin</i> mRNA	0.07 [0.01–1.27]	0.08 [0.01–1.81]	ns
<i>CCNB1/βactin</i> mRNA	0.57 [0.05–2.75]	0.70 [0.11–1.78]	ns
<i>Caspase 3/βactin</i> mRNA	0.32 [0.01–1.36]	0.15 [0.01–1.98]	ns
<i>AIP/βactin</i> mRNA	6.80 [0.29–33.9]	3.25 [1.03–7.27]	0.024
<i>D2R/βactin</i> mRNA	7.71 [0.08–213]	3.85 [0.44–49.2]	ns
III. Immunohistochemistry			
D2R mAb ^a	1/11 (9.0%)	1/4 (25.0%)	ns
D2R pAb ^a	9/13 (69.2%)	1/2 (50.0%)	ns
AIP ^a	25/34 (73.5%)	4/6 (66.7%)	ns
AIP score	3 [1–6]	3 [1–4]	ns

^aPositive immunostaining

The expression of all genes was subsequently analyzed in a correlation matrix, including patients' age and the Ki67 LI (Table 2). *SF1* was found to strongly and positively correlate with *βLH* and *D2R* expression ($r = 0.506$ and $r = 0.477$, $P < 0.001$ for both), to a lesser extent with *AIP* ($r = 0.442$, $P = 0.002$), but not with *βFSH* expression ($r = 0.186$, $P = ns$). No correlation was found between *SF1* and the Ki67 LI or any marker of the cell cycle (*CCND1*, *CCNA2*, *CCNB1*), except for a non-significative trend with *caspase 3* ($r = 0.293$, $P = 0.054$), which also tended to decrease with age ($r = -0.286$, $P = 0.057$).

Cell Cycle Markers and Tumor Characteristics

As compared with normal pituitaries, *CCNB1* was found to be upregulated (> 75° or 90° percentile) in 94.7% of cases, whereas *CCND1* and *CCNA2* were upregulated in 28.9% and 77.6%, respectively. The Ki67 LI was found to positively correlate with *CCNB1* ($r = 0.512$, $P = 0.001$) but negatively

correlated with *CCND1* ($r = -0.382$, $P = 0.008$). Accordingly, as shown in Fig. 2, *CCNB1* expression was significantly higher but *CCND1* expression was significantly lower in “high Ki67” than in “low Ki67” tumors ($P = 0.002$ and $P = 0.041$, respectively). In contrast, no significant correlation was found between the Ki67 LI and *CCNA2* or *caspase 3*, which did not differ between “high Ki67” and “low Ki67” tumors (data not shown). Similarly, the expression of gene encoding cyclins and the Ki67 LI were not significantly different in recurrent vs non-recurrent tumors, and recurrent GnPT were only characterized by a significantly lower *βLH* and *D2R* gene expression and a trend towards a lower *CCND1* expression (Supplementary Table 1).

Factors Associated with AIP Expression

Because, as reported above, *AIP* transcripts were found to be significantly lower in pSF1 tumors ($P = 0.024$ vs FSH/LH tumors), we further analyzed factors influencing AIP expression in GnPT. As shown in the correlation matrix, *AIP* transcripts were found to significantly and positively correlate with *βLH* ($r = 0.391$, $P = 0.009$), *βFSH* ($r = 0.291$, $P = 0.041$), and *CCND1* ($r = 0.391$, $P = 0.008$) but were unrelated to *CCNA2*, *CCNB1*, or the Ki67 LI (Table 2). Among the 40 cases studied for AIP-IHC, 29 (72.5%) showed AIP immunostaining, out of which 15 (37.5%) had a high AIP score. Although *AIP* transcripts were significantly higher in the presence of a high AIP score ($P = 0.035$ vs a low AIP score) (Fig. 3), the median AIP immunostaining score was similar in the 2 groups of GnPT (Table 1), and the proportion of tumors with a high AIP score was similar in “high Ki67” and in “low Ki67” tumors (33.3% vs 40%, respectively). This was confirmed in the FSH/LH subgroup (45.4% vs 40.9%, respectively).

In addition, no significant difference was found in the AIP gene or protein expression according to the patient's gender, tumor size, invasiveness, or recurrence (data not shown).

Examples of AIP and SF1 immunostaining are shown in Supplemental Fig. 2.

Factors Associated with D2R Expression

D2R transcripts were detectable in all cases, similar expression observed in a control series of functional lactotroph tumors (Fig. 4A), and significantly lower in recurrent cases ($P = 0.043$ vs non-recurrent cases) (Fig. 4B).

As shown in the correlation matrix, *D2R* transcripts were strongly and positively correlated with *SF1* and *AIP* ($P < 0.001$ for both), to a lesser extent with *βFSH* ($P = 0.002$), *βLH* ($P = 0.014$), and *CCND1* ($P = 0.026$) but not with *CCNB1*, *CCNA2*, *caspase 3*, or the Ki67 LI (Table 2). However, the difference between the 2 groups of GnPT did not




Fig. 1 Bio-clinical characteristics of GnPT according to the presence or absence of gonadotropin immunostaining. Patients with FSH and/or LH immunostaining GnPT were significantly younger than those operated for pSF1 tumors (A), with no difference in tumor size (B) or Ki67

labeling index (%) (C) between the 2 groups. A significantly higher expression of βFSH and AIP was observed in the first group (D–G)

reach significance, and no significant variations were found according to tumor size or invasiveness.

Both the antibodies used for the evaluation of D2R protein expression by IHC—one monoclonal (D2R mAb) and one polyclonal (D2R pAb)—showed immunopositivity on a control brain sample (Fig. 5A, B). In such tissue, a clear cytoplasmic immunostaining was observed, with occasional membrane staining. However, in the study of normal pituitary fragments contaminating unselected samples of PitNETs, D2R immunostaining was mostly observed using the D2R pAb, which revealed cytoplasmic but also membrane staining in a subset of cells (Fig. 5C, D). Unexpectedly, using the D2R mAb, D2R immunostaining on NP fragments was mostly nuclear. Individual data obtained with either antibody on a series of functional lactotroph tumors and GnPT are detailed in Supplemental Table 2, and representative examples are shown in Fig. 5E, F. Based on such data, no quantitative score could be proposed. To summarize, D2R pAb showed some degree of cytoplasmic staining in 8/9 functional lactotroph tumors, with a membrane staining in 5/9 cases, although immunopositivity was focal or scattered. On the contrary, a single case of functional lactotroph tumor showed diffuse cytoplasmic and nuclear immunostaining using the D2R mAb. In a subset of GnPT, representative of different levels of *D2R* gene expression,

only some nuclear, and generally faint, immunopositivity was observed using the mAb. Instead, a clear immunopositivity was observed in 10/15 cases using the D2R pAb (Fig. 5G, H), although it appeared mostly cytoplasmic and detectable at membrane level in a single case.

Discussion


To the best of our knowledge, this study is the first to provide a clinicopathological and molecular characterization of GnPT according to their immunoprofile. As compared to FSH/LH-immunopositive GnPT, pSF1 tumors tended to occur in older patients and displayed a lower gene expression of βFSH and AIP but did not significantly differ in terms of gender, tumor size, invasiveness, Ki67, or any marker of cell cycle or apoptosis. This is relevant since pSF1 tumors previously belonged to the previous “null cell” group of PitNETs, which are now defined by the absence of lineage-specific transcription factor expression [3, 4], so a re-evaluation of the potentially worse prognosis of “null cell” tumors among NFPT needs some re-evaluation in light of the pituitary lineage of origin of hormone-negative cases [2]. In a recent study, “null cell” pituitary tumors were still reported to be more at risk than GnPT (which included pSF1 cases), albeit

Table 2 Gene expression data obtained in 54 GnPT: correlation matrix

	SF1 mRNA	β FSH mRNA	β LH mRNA	CCND1 mRNA	CCNA2 mRNA	CCNB1 mRNA	Caspase 3 mRNA	AIP mRNA	D2R mRNA	Ki67	Age
SF1 mRNA	Spearman's rho	–									
	<i>p</i> value	–									
β FSH mRNA	Spearman's rho	0.186	–								
	<i>p</i> value	0.181	–								
β LH mRNA	Spearman's rho	0.506	0.144	–							
	<i>p</i> value	<.001	0.328	–							
CCND1 mRNA	Spearman's rho	0.267	0.222	0.346	–						
	<i>p</i> value	0.067	0.125	0.024	–						
CCNA2 mRNA	Spearman's rho	0.209	–0.174	0.064	–						
	<i>p</i> value	0.172	0.253	0.342	0.678	–					
CCNB1 mRNA	Spearman's rho	–0.008	–0.067	0.094	–0.137	–					
	<i>p</i> value	0.964	0.688	0.574	0.411	–					
Caspase 3 mRNA	Spearman's rho	0.293	–0.037	0.452	0.394	0.096	–				
	<i>p</i> value	0.054	0.808	0.003	0.007	0.566	–				
AIP mRNA	Spearman's rho	0.442	0.291	0.378	0.200	–0.311	0.291	–			
	<i>p</i> value	0.002	0.041	0.009	0.008	0.058	0.053	–			
D2R mRNA	Spearman's rho	0.477	0.415	0.354	0.187	–0.199	0.094	0.557	–		
	<i>p</i> value	<.001	0.002	0.014	0.137	0.231	0.539	<.001	–		
Ki67	Spearman's rho	0.091	–0.110	–0.092	0.295	0.512	–0.171	–0.205	–0.117	–	
	<i>p</i> value	0.526	0.438	0.541	0.008	0.001	0.273	0.162	0.408	–	
Age	Spearman's rho	–0.339	0.082	–0.068	–0.150	0.118	–0.286	–0.171	–0.068	0.001	–
	<i>p</i> value	0.013	0.555	0.647	0.324	0.480	0.057	0.234	0.625	0.994	–

Significant values are indicated in bold (nearly significant trends in *italics*)

Fig. 2 *CCNB1* and *CCND1* gene expression in GnPT according to the Ki67 LI. “High Ki67” GnPT had significantly higher *CCNB1* expression but significantly lower *CCND1* expression than “low Ki67” tumors



due to the retrospective nature of the study, the expression of lineage-specific transcription factors was not available on all “null cell” tumors [22]. A lower, patchy expression of SF1 in GnPT was also found to be more frequently associated with post-operative recurrences than a higher, diffuse expression of SF1 and that the transcriptional profile of low SF1-expressing tumors suggested an increased activation of the PI3K/Akt pathway [23]. According to this study, the SF1 labeling index was more accurate than Ki67 in predicting short-term recurrences [23]. Nonetheless, data from the current study suggest that *SF1* gene expression is similar in the two groups of GnPT and that pSF1 tumors do not represent per se a distinct “high-risk” tumor phenotype. Of note, because Pit1 and Tpit expression were evaluated by RT-PCR in all samples, primarily to exclude contamination by normal pituitary fragments, we are sufficiently confident

that only GnPT were included and that SF1 immunostaining was not the expression of a potential co-lineage [24]. Large follow-up studies would be useful to verify the recurrence risk of pSF1 tumors.

Another interesting finding of this study is that *SF1* gene expression was found to significantly decrease with patients’ age and significantly correlated with β LH but not with β FSH expression. The strong correlation between *SF1* and β LH ($P < 0.001$) is consistent with the direct transcriptional role of SF1 in the positive control of β LH expression reported in rodents, involving SF1-binding-sites in its 5’ flanking promoter region [25]. This has also been shown in the sheep pituitary, with an SF1-binding site being identified in the β LH but not in the β FSH promoter [26]. Nonetheless, SF1 may indirectly enhance β FSH transcription in normal gonadotrophs through GnRH stimulation [25, 27]. Receptors for sex steroids [28] and other transcription factors are also involved in the regulation of gonadotropins [29, 30]. The functional heterogeneity of GnPT was pointed out in a recent study which reported, based on quantitative immunohistochemistry for gonadotropins, a majority of cases showing both FSH and LH (74.5%) immunopositivity, followed by pure FSH- (21.4%) and a very minority of pure LH-immunopositive tumors (4.1%) [31]. Significant differences in the expression of ER α and the somatostatin receptor SST2 were found between these subgroups, suggesting that functional differences may reflect different pathogenetic mechanisms and have translational implications [31]. In the present study, no significant difference was found in *SF1* expression between FSH/LH and pSF1 tumors, and no correlation was found between *SF1* and the Ki67 LI or any marker of cell cycle, which may be in contrast with the recurrences observed in low SF1 expressing GnPT [23]. Because we did not perform SF1 immunostaining in the presence of unequivocal gonadotropin immunostaining, we could not assess this point, but the lower β LH transcripts





Fig. 3 Correlation between AIP gene expression and immunostaining in GnPT. AIP transcripts were significantly higher in tumors expressing a high AIP immunostaining score (≥ 4)

Fig. 4 *D2R* gene expression in GnPT and functional lactotroph tumors. No significant difference in *D2R* expression was found between functional lactotroph tumors (PRL) and GnPT, or between FSH/LH and pSF1 phenotypes (A). In contrast, *D2R* transcripts were significantly lower in recurrent GnPT as compared to non-recurrent cases (B)



observed in recurrent cases might be an indirect index of a lower SF1 transcriptional activity. On the other hand, we found that *SF1* gene expression was significantly correlated with that of *AIP* and *D2R*.

A strong positive correlation was indeed observed for the first time between *AIP* and the three markers of gonadotroph phenotype, *SF1*, β *LH*, and β *FSH*. The paradoxical *AIP* gene and/or protein expression was already reported in GnPT [17–19]. In the present study, *AIP* immunostaining was also observed in nearly 75% of the cases, nearly half of which with a high score. Although *AIP* transcripts were significantly higher in the presence of a high *AIP* score and in FSH/LH-GnPT, the *AIP* immunoscore was not significantly higher in this latter group as compared to pSF1 cases. Overexpression of mir-107 targeting *AIP* mRNA has been involved in NFPT and may account for some discrepancy between *AIP* gene and protein expression [32]. However, the mechanisms leading to paradoxical *AIP* expression in GnPT and its potential implications are unclear. No relationship has been found between *AIP* expression and tumor invasiveness [19, this study]. In contrast, high *AIP* immunostaining was previously reported in 83% of FSH/LH-GnPT with a high Ki67 (>3%) and 21% of those with a low Ki67, further suggesting an opposite pattern as compared to somatotropinomas [19]. We were unable to confirm such findings in a larger series of GnPT. Indeed, the proportion of tumors with a high *AIP* score was similar in “high Ki67” and in “low Ki67” tumors, and this was confirmed in the FSH/LH-immunopositive subgroup. *AIP* gene expression also appeared to be unrelated to the Ki67 LI. To further investigate the potential relationship between *AIP* and cell proliferation in GnPT, we also analyzed the relationship between the transcriptional expression of *AIP* and genes encoding cyclins found to be overexpressed in NFPT [33], namely cyclin D1 [34–39], cyclin A2 [40, 41], and cyclin B1 [42, 43]. A positive correlation was observed between the transcriptional levels of *AIP*

and *CCND1*, which encodes cyclin D1, a known target of extracellular stimulation by mitotic growth factors and consistently reported to be overexpressed in NFPT—as defined before the introduction of transcription factors to identify their lineage of origin [34–39]. Extra-cellular factors may thus contribute to increase *AIP* expression in GnPT. In contrast, we found *AIP* to be unrelated to *CCNA2* and negatively correlated with *CCNB1*. However, *CCNB1* was significantly higher in “high Ki67” tumors ($\geq 3\%$), whereas *CCND1* was significantly higher in “low Ki67” cases (<3%), *CCNA2* being similar in both groups. Overall, these data argue against a role of *AIP* in the proliferative or invasive potential of GnPT. Therefore, if *AIP* is a well-documented tumor suppressor gene in somatotroph PitNETs, current data do not support a potential, opposite, oncogenic function for *AIP* in GnPT—as recently reported in some non-endocrine neoplasms [44]. This suggests that *AIP* expression has no prognostic value in GnPT, although follow-up studies may be useful to further validate this point.

This study also unraveled an intriguing discrepancy between *CCND1* and *CCNB1*, with opposite variations according to the Ki67 LI. *CCNB1* overexpression in GnPT has previously been associated with downregulation of miR-410, which decreases *CCNB1* transcription and enhances its degradation [45]. Because cyclin B1 is expressed in the G2/M transition and is essential for the initiation of mitosis [46], it is not surprising that *CCNB1* expression may be indicative of tumor proliferation. In contrast, cyclin D1 is involved early in the cell cycle, but initial progression into the cell cycle may not necessarily lead to proliferation. Our findings are reminiscent of the opposite role of cyclin B1/2 and cyclinD1 during neurogenesis, coordinating cortical progenitor self-renewal and lineage commitment [47]. In this model, cyclin D1 promoted cell differentiation [47]. An attractive hypothesis is that, in GnPT, cyclin D1 and cyclin B1 may also contribute to differentially control cell function




Fig. 5 D2R immunostaining in controls and representative examples of GnPT using a monoclonal (D2R-mAb) or a polyclonal (D2R-pAb) antibody. In the brain tissue (**A, B**) ($\times 200$ magnification; inset at $\times 400$), D2R staining was essentially cytoplasmic. In normal pituitary gland fragments, nuclear (**C**) or cytoplasmic with occasional membrane (**D**) D2R staining was observed ($\times 200$ magnification; inset at $\times 400$). Similar results were obtained on functional lactotroph tumors (**E, F**) ($\times 200$

magnification; inset at $\times 400$). Representative examples of D2R immunostaining in GnPT are also shown (**G, H**) using the mAb (**G**) nuclear staining which was observed in a normal juxta-tumoral pituitary fragment (indicated by a star) and in scattered neoplastic cells (inset) ($\times 100$ magnification; inset at $\times 400$), whereas cytoplasmic staining was focally observed with the pAb (**H**) ($\times 400$ magnification)

and proliferation, respectively. Further *in vitro* studies would be useful to explore such hypothesis and clarify the potential prognostic role of cyclin D1 overexpression, which is a

preferential feature of NFPT [34–39]. Indeed, correlations between cyclin D1 immunostaining and the Ki67 LI and tumor volume and cavernous sinus invasion were observed

on a representative series of PT including NFPT but not specifically detailed in this subgroup [39], and the same occurred in a subgroup of aggressive PT [36]. The highest cyclin D LI reported in NFPT compared to other phenotypes was observed for both recurrent and tumors [33]. In addition, in our series, *CCND1* expression tended to be lower in recurrent cases, but cyclin D1 has a short half-life, and protein overexpression appears to be generally modest [34–36], and not correlated with mRNA levels [34]. Therefore, the impact of our findings on cyclin D1 protein expression should be further evaluated. *CCNA2*, which encodes cyclin A2, involved at an intermediate stage of the cell cycle, was modestly correlated with *CCNB1* and tended to correlate with the Ki67 LI but was unrelated to *CCND1*, *AIP*, or any marker of gonadotroph phenotype. The cyclin B/A immunostaining ratio was also previously reported to be higher in nonfunctioning pituitary tumors that regrew compared to those who did not [33]. Overall, it appears that cyclin B1/*CCNB1* may be the best marker of cell proliferation in GnPT, and further studies, including immunohistochemistry and prospective follow-up, could be designed to evaluate its potential prognostic value in such tumors.

The expression of D2R was also investigated because of its potential translational impact. We found *D2R* gene expression to be significantly correlated with that of *AIP*, the three markers of gonadotroph phenotype—in particular *SF1*—and to a lesser extent *CCND1*. In a recent preliminary report, *D2R* mRNA appeared to be lower in pSF1 than in gonadotropin-expressing GnPT [48], but this point was not confirmed when enlarging the series for the final study, and median D2R levels were also similar among the 2 groups of GnPT and in functional lactotroph tumors taken as controls. However, D2R expression was found to be significantly lower in recurrent GnPT. In one study comparing the efficacy of post-operative dopamine-agonist drugs given either as a preventive treatment of tumor regrowth or as a remedial treatment in recurrent cases, additional surgery or radiotherapy was required in 13% of the preventive group, versus 38% of the remedial group and 42% of the untreated control group [13]. Taken together, these data suggest that the potential response to DA may decrease during tumor progression. The present study points out that a major limitation in the study of D2R protein expression in PitNETs is the poor reliability of current IHC procedures, with limited evidence of membrane staining. Another limitation was the heterogeneity of tumor staining, which was found also on functional lactotroph tumors. Thus, despite the use of two antibodies in different experimental conditions, we were unable to set a quantitative score for D2R immunostaining and reliably analyze the protein correlates of *D2R* gene expression. An interesting finding, however, is that membrane staining, which could be observed on control sections (brain,

normal pituitary, functional lactotroph tumors) was exceptionally found in GnPT, and only using the polyclonal antibody. If *D2R* transcripts were previously reported to be higher in DA-responsive NFPT, especially in their short isoform [11], the predictive value of D2R immunostaining is controversial and overall disappointing. Some informative value was suggested in one study [12] but not by others [13, 49], D2R staining being mostly cytoplasmic in all studies. Defective anchorage of D2R (as well as SSTRs) in PitNETs may be due to low or absent filamin-A expression and account for resistance to DA, although this has not been specifically studied in GnPT [50]. Therefore, if focal expression and inappropriate D2R localization may contribute to the inconstant and moderate response of GnPT to DA in clinical practice, the current predictive value of D2R immunostaining is poor and discourages its use for the selection of potentially responsive patients, and technical optimization is warranted.

In conclusion, this study suggests that pSF1 tumors tend to develop later in life as compared to gonadotropin-expressing GnPT, but do significantly differ from this latter group—which is the most commonly encountered—in terms of macroscopic characteristics, Ki67, and *SF1* or cyclin gene expression. *AIP* expression in GnPT appeared to be unrelated to invasion or proliferation. D2R may be mislocalized in GnPT, but D2R immunostaining still requires optimization. Thus, at the moment, *AIP* and D2R immunostaining appear to be poorly relevant for clinical practice in these tumors. In contrast, cyclin B1 appears as a promising marker of proliferation in GnPT, and its potential prognostic value would deserve further studies. Similarly, the potential prognostic value of cyclin D1 immunostaining in NFPT should be further clarified.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s12022-023-09794-w>.

Acknowledgements The authors thank Maria-Antonietta Oliva and Sabrina Staffieri for excellent technical assistance in samples handling and immunohistochemical studies.

Authors' Contribution M.L.J.R. and Fe. G. designed and organized the study. F. C. and M.L.J.R. elaborated final results and wrote the main manuscript text. F. C. and M.A.P. performed the molecular experiments. F.C. also prepared graphs and tables. T.F. collected clinical data - included intra-operative tumor characteristics with M.D.A. and R. M. - and contributed to the manuscript editing and scientific content with D.D.A. A.A. contributed to proper sample collection and tumor characterization with Fr.G. and R.M.D.C., who both evaluated immunostaining data and prepared the relative illustrations. V.E. operated the patients with M.D.A. and R.M. All the authors provided multidisciplinary scientific expertise and comments, reviewed and approved the manuscript.

Funding This study was partially supported by the Italian Ministry for University and Research (exRIA 60% to MLJR), the Carlo Ferri foundation for the prevention of cancer (Monterotondo, RM) to MLJR, Current Research from Neuromed IRCCS (Pozzilli, IS), and Project ECS

0000024 Rome Technopole, CUP B83C22002820006, PNRR Missione 4 Componente 2 Investimento 1.5, funded by NextGenerationEU to TF.

Data Availability Raw data are available at the Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, and at the Neuromed IRCCS, Pozzilli, Italy.

Declarations

Ethics Approval The study was performed according to the guidelines of the Declaration of Helsinki and approved by the Internal Review Board of the Neuromed IRCCS (Pozzilli, Italy).

Competing Interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Ntali G, Capatina C, Grossman A, Karavitaki N (2014) Clinical review: Functioning gonadotroph adenomas. *J Clin Endocrinol Metab* 99:4423–4433. <https://doi.org/10.1210/jc.2014-2362>
- Drummond J, Roncaroli F, Grossman AB, Korbonits M (2019) Clinical and Pathological Aspects of Silent Pituitary Adenomas. *J Clin Endocrinol Metab* 104:2473–2489. <https://doi.org/10.1210/jc.2018-00688>
- Mete O, Lopes MB (2017) Overview of the 2017 WHO Classification of Pituitary Tumors. *Endocr Pathol* 28:228–243. <https://doi.org/10.1007/s12022-017-9498-z>
- Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. *Endocr Pathol* 33:6–26. <https://doi.org/10.1007/s12022-022-09703-7>
- Mete O, Cintosun A, Pressman I, Asa SL (2018) Epidemiology and biomarker profile of pituitary adenohypophysial tumors. *Mod Pathol* 31:900–909. <https://doi.org/10.1038/s41379-018-0016-8>
- Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansoorge O, Asioli S, Barresi V, Chinezu L, Gardiman MP, Lania A, Lapshina AM, Poliani L, Reiniiger L, Righi A, Saeger W, Soukup J, Theodoropoulou M, Uccella S, Trouillas J, Roncaroli F (2019) A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. *Virchows Arch* 475:687–692. <https://doi.org/10.1007/s00428-019-02655-0>
- Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okada M, Takeuchi Y, Yamada S (2015) The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. *Endocr Pathol* 26:349–355. <https://doi.org/10.1007/s12022-015-9398-z>
- Spada A, Mantovani G, Lania AG, Treppiedi D, Mangili F, Catalano R, Carosi G, Sala E, Peverelli E (2022) Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior. *Neuroendocrinology* 112:15–33. <https://doi.org/10.1159/000514862>
- Greenman Y, Bronstein MD (2021) Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. *Eur J Endocrinol* 185:D11–D20. <https://doi.org/10.1530/EJE-21-0344>
- Even-Zohar N, Greenman Y (2022) Current medical treatment and perspective in gonadotroph tumors. *Best Pract Res Clin Endocrinol Metab* 36:101685. <https://doi.org/10.1016/j.beem.2022.101685>
- Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G (2004) Dopamine receptor expression and function in clinically non-functioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. *J Clin Endocrinol Metab* 89:1674–1683. <https://doi.org/10.1210/jc.2003-030859>
- Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV, Gasparetto EL, de Castro M, Takiya CM, Gadelha MR (2015) Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. *Clin Endocrinol (Oxf)* 82:739–746. <https://doi.org/10.1111/cen.12684>
- Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, Yuan X, Gertych A, Shimon I, Ram Z, Melmed S, Stern N (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. *Eur J Endocrinol* 175:63–72. <https://doi.org/10.1530/EJE-16-0206>
- Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TML, Salmela PI, Paschke R, Gündogdu S, De Menis E, Mäkinen MJ, Launonen V, Karhu A, Aaltonen LA (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. *Science* 312:1228–1230. <https://doi.org/10.1126/science.1126100>
- Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. *Endocr Rev* 34:239–277. <https://doi.org/10.1210/er.2012-1013>
- Srirangam Nadhamuni V, Korbonits M (2020) Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. *Endocr Rev* 41:821–846. <https://doi.org/10.1210/endrev/bnaa006>
- Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JAH, Popovic V, Ribeiro-Oliveira A, Gadelha MR, Monson JP, Akker SA, Davis JRE, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. *J Clin Endocrinol Metab* 93:2390–2401. <https://doi.org/10.1210/jc.2007-2611>
- Jaffrain-Rea M-L, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen J-F, D'Innocenzo E, Barlier A, Giangaspero F, Esposito V, Ventura L, Arcella A, Theodoropoulou M, Naves LA, Fajardo C, Zacharieva S, Rohmer V, Brue T, Gulino A, Cantore G, Alesse E, Beckers A (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. *Endocr Relat Cancer* 16:1029–1043. <https://doi.org/10.1677/ERC-09-0094>
- Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM, Gadelha MR (2011) Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. *Neuroendocrinology* 94:39–48. <https://doi.org/10.1159/000322787>
- Fratticci A, Grieco FA, Spilioti C, Giangaspero F, Ventura L, Esposito V, Piccirilli M, Santoro A, Gulino A, Cantore G, Alesse

- E, Jaffrain-Rea ML (2007) Differential expression of neurogenins and NeuroD1 in human pituitary tumours. *J Endocrinol* 194:475–484. <https://doi.org/10.1677/JOE-07-0020>
21. Jaffrain-Rea M-L, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, Rostomyan L, Defilles C, Angelini M, Oliva M-A, Ceccato F, Maiorani O, Daly AF, Esposito V, Buttarelli F, Figarella-Branger D, Giangaspero F, Spada A, Scaroni C, Alesse E, Beckers A (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. *Endocr Relat Cancer* 20:753–766. <https://doi.org/10.1530/ERC-12-0322>
 22. Haddad AF, Young JS, Oh T, Pereira MP, Joshi RS, Pereira KM, Osorio RC, Donohue KC, Peeran Z, Sudhir S, Jain S, Beniwal A, Chopra AS, Sandhu NS, Theodosopoulos PV, Kunwar S, El-Sayed IH, Gurrola J, Blevins LS, Aghi MK (2020) Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. *Neurosurg Focus* 48:E13. <https://doi.org/10.3171/2020.3.FOCUS20114>
 23. Hickman RA, Bruce JN, Otten M, Khandji AG, Flowers XE, Siegelin M, Lopes B, Faust PL, Freda PU (2021) Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway. *Neuropathol Appl Neurobiol* 47:415–427. <https://doi.org/10.1111/nan.12675>
 24. Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson M-L, Septier A, Letourneur F, Diry S, Diedisheim M, Izac B, Gaspar C, Perlemoine K, Verjus V, Bernier M, Boulin A, Emile J-F, Bertagna X, Jaffrezic F, Laloe D, Baussart B, Bertherat J, Gaillard S, Assié G (2020) Pangenomic Classification of Pituitary Neuroendocrine Tumors. *Cancer Cell* 37:123–134.e5. <https://doi.org/10.1016/j.ccell.2019.11.002>
 25. Kaiser UB, Halvorson LM, Chen MT (2000) Sp1, steroidogenic factor 1 (SF-1), and early growth response protein 1 (egr-1) binding sites form a tripartite gonadotropin-releasing hormone response element in the rat luteinizing hormone-beta gene promoter: an integral role for SF-1. *Mol Endocrinol* 14:1235–1245. <https://doi.org/10.1210/mend.14.8.0507>
 26. Brown P, Mcneilly AS (1997) Steroidogenic factor-1 (SF-1) and the regulation of expression of luteinising hormone and follicle stimulating hormone b-subunits in the sheep anterior pituitary in vivo. *Int J Biochem Cell Biol* 29:1513–1524. [https://doi.org/10.1016/s1357-2725\(97\)00082-4](https://doi.org/10.1016/s1357-2725(97)00082-4)
 27. Bakke M, Zhao L, Hanley NA, Parker KL (2000) Approaches to define the role of SF-1 at different levels of the hypothalamic-pituitary-steroidogenic organ axis. *Endocr Res* 26:1067–1073. <https://doi.org/10.3109/07435800009048639>
 28. Mahesh VB, Brann DW (1998) Neuroendocrine mechanisms underlying the control of gonadotropin secretion by steroids. *Steroids* 63:252–256. [https://doi.org/10.1016/s0039-128x\(98\)00031-2](https://doi.org/10.1016/s0039-128x(98)00031-2)
 29. Aylwin SJ, Welch JP, Davey CL, Geddes JF, Wood DF, Besser GM, Grossman AB, Monson JP, Burrin JM (2001) The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas. *J Clin Endocrinol Metab* 86:2476–2483. <https://doi.org/10.1210/jcem.86.6.7531>
 30. Fortin J, Kumar V, Zhou X, Wang Y, Auwerx J, Schoonjans K, Boehm U, Boerboom D, Bernard DJ (2013) NR5A2 regulates Lhb and Fshb transcription in gonadotrope-like cells in vitro, but is dispensable for gonadotropin synthesis and fertility in vivo. *PLoS One* 8:e59058. <https://doi.org/10.1371/journal.pone.0059058>
 31. Ilie MD, Vasiljevic A, Louvet C, Jouanneau E, Raverot G (2020) Gonadotroph Tumors Show Subtype Differences that Might Have Implications for Therapy. *Cancers* 12:1012. <https://doi.org/10.3390/cancers12041012>
 32. Trivellini G, Butz H, Delhove J, Igreja S, Chahal HS, Zivkovic V, McKay T, Patócs A, Grossman AB, Korbonits M (2012) MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. *Am J Physiol Endocrinol Metab* 303:E708–719. <https://doi.org/10.1152/ajpendo.00546.2011>
 33. Turner HE, Nagy Z, Sullivan N, Esiri MM, Wass JA (2000) Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. *Clin Endocrinol (Oxf)* 53:337–344. <https://doi.org/10.1046/j.1365-2265.2000.01088.x>
 34. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Góth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB (2009) Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. *Endocr Relat Cancer* 16:1329–1338. <https://doi.org/10.1677/ERC-09-0101>
 35. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, Farrell WE (1999) Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. *Clin Cancer Res* 5:2133–2139
 36. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB (2000) Cyclin D and cyclin E expression in normal and adenomatous pituitary. *Eur J Endocrinol* 143:R1–6. <https://doi.org/10.1530/eje.0.143r001>
 37. Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN, Farrell WE (2001) Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. *Carcinogenesis* 22:1149–1154. <https://doi.org/10.1093/carcin/22.8.1149>
 38. Muşat M, Morris DG, Korbonits M, Grossman AB (2010) Cyclins and their related proteins in pituitary tumorigenesis. *Mol Cell Endocrinol* 326:25–29. <https://doi.org/10.1016/j.mce.2010.03.017>
 39. Gruppetta M, Formosa R, Falzon S, Ariff Scicluna S, Falzon E, Degeatano J, Vassallo J (2017) Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas. *Pituitary* 20:358–371. <https://doi.org/10.1007/s11102-017-0803-0>
 40. Nakabayashi H, Sunada I, Hara M (2001) Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. *J Histochem Cytochem* 49:1193–1194. <https://doi.org/10.1177/002215540104900916>
 41. Lamback EB, Guterres A, Barbosa MA, Lima, C.H.D.A., Silva, D.A., Camacho, A.H.D.S., Chimelli, L., Kasuki, L. and Gadelha, M.R. (2020) Cyclin A in nonfunctioning pituitary adenomas. *Endocrine* 70:380–387. <https://doi.org/10.1007/s12020-020-02402-5>
 42. Zhao P, Zhang P, Hu W, Wang H, Yu G, Wang Z, Li C, Bai J, Zhang Y (2017) Upregulation of cyclin B1 plays potential roles in the invasiveness of pituitary adenomas. *J Clin Neurosci* 43:267–273. <https://doi.org/10.1016/j.jocn.2017.05.005>
 43. Cheng J, Nie D, Li B, Gui S, Li C, Zhang Y, Zhao P (2021) Circ-NFIX promotes progression of pituitary adenoma via CCNB1 by sponging miR-34a-5p. *Mol Cell Endocrinol* 525:111140. <https://doi.org/10.1016/j.mce.2020.111140>
 44. Haworth O, Korbonits M (2022) AIP: A double agent? The tissue-specific role of AIP as a tumour suppressor or as an oncogene. *Br J Cancer* 127:1175–1176. <https://doi.org/10.1038/s41416-022-01964-7>
 45. Müssnich P, Raverot G, Jaffrain-Rea M-L, Frassetto F, Wierinckx A, Trouillas J, Fusco A, D'Angelo D (2015) Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. *Cell Cycle* 14:2590–2597. <https://doi.org/10.1080/15384101.2015.1064207>
 46. Innocente SA, Abrahamson JLA, Cogswell JP, Lee JM (1999) p53 regulates a G2 checkpoint through cyclin B1. *Proceedings of the National Academy of Sciences* 96:2147–2152. <https://doi.org/10.1073/pnas.96.5.2147>

47. Hagey DW, Topcic D, Kee N, Reynaud F, Bergsland M, Perlmann T, Muhr J (2020) CYCLIN-B1/2 and -D1 act in opposition to coordinate cortical progenitor self-renewal and lineage commitment. *Nat Commun* 11:2898. <https://doi.org/10.1038/s41467-020-16597-8>
48. Carbonara F, Feola T, Gianni F, De Angelis M, Morace R, Giangaspero F, Jaffrain-Rea ML (2023) Caratteristiche cliniche e molecolari dei tumori neuroendocrini gonadotropinici (Gn-PitNETs) in base ai sottogruppi definiti dalla WHO XII Incontri Italiani malattie Ipotalamo-Ipofisarie (4I), 9-11 February. Genova, Italy
49. Batista RL, Musolino NRC, Cescato VAS, da Silva GO, Medeiros RSS, Herkenhoff CGB, Trarbach EB, Cunha-Neto MB (2019) Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial. *Am J Clin Oncol* 42:221–227. <https://doi.org/10.1097/COC.0000000000000505>
50. Treppiedi D, Catalano R, Mangili F, Mantovani G, Peverelli E (2022) Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer. *Endocr Oncol* 2:R143–R152. <https://doi.org/10.1530/EO-22-0055>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com